MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-28, PFE had -$301M decrease in cash & cash equivalents over the period. $4,001M in free cash flow.

Cash Flow Overview

Change in Cash
-$301M
Free Cash flow
$4,001M

Unit: Million (M) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-28
2025-06-29
2025-03-30
2024-12-31
Net income from continuing operations before allocation to noncontrolling interests
3,551 2,903 2,973 411
Depreciation and amortization
1,662 1,625 1,618 1,791
Asset write-offs and impairments
366 154 344 3,162
Deferred taxes
-765 -272 -663 -396
Share-based compensation expense
201 203 170 177
Benefit plan contributions in excess of expense/income
84 105 229 -454
Inventory write-offs and related charges associated with covid-19 products
---0
Other adjustments, net
292 101 -40 1,805
Trade accounts receivable
---109
Inventories
---854
Other assets
----3,380
Trade accounts payable
----1,023
Other liabilities
----3,115
Other tax accounts, net
----1,345
Other changes in assets and liabilities, net of acquisitions and divestitures
36 4,989 -4,073 -
Net cash provided by/(used in) operating activities
4,603 -582 2,335 6,721
Purchases of property, plant and equipment
602 618 564 917
Purchases of short-term investments
4,223 3,262 2,823 6,176
Proceeds from redemptions/sales of short-term investments
2,736 6,545 3,955 1,498
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
583 -1,184 3,852 -487
Purchases of long-term investments
129 -48 134 105
Proceeds from redemptions/sales of long-term investments
359 63 82 29
Proceeds from sale of investment in haleon
0 0 6,311 3,549
Acquisitions of businesses, net of cash acquired
---0
Dividend received from the consumer healthcare jv
---0
Other investing activities, net
-14 12 -313 -
Net cash provided by/(used in) investing activities
-2,430 3,951 3,274 -1,623
Proceeds from short-term borrowings
0 0 0 732
Payments on short-term borrowings
0 151 2,048 3,452
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
6 -517 -386 0
Proceeds from issuance of long-term debt
0 3,687 -0
Payments on long-term debt
0 3,750 0 0
Purchases of common stock
---0
Cash dividends paid
2,444 2,445 2,437 2,380
Other financing activities, net
-38 -21 -356 -14
Net cash provided by/(used in) financing activities
-2,477 -3,196 -5,227 -5,114
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
2 41 -7 -29
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
-301 213 375 -45
Cash and cash equivalents at beginning of period
1,694 1,481 1,107 1,152
Cash and cash equivalents at end of period
1,394 1,694 1,481 1,107
Unit: Million (M) dollars

Time Plot

Show the time plot by selecting a row from the table.

Pfizer_(2021)-svg

PFIZER INC (PFE)

Pfizer_(2021)-svg

PFIZER INC (PFE)